Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 14, 2015; 21(38): 10811-10823
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10811
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10811
Table 3 The worldwide prevalence of hepatitis C virus genotypes
Area | The most prevalent genotype | Frequency of other genotypes | First author |
North America | G1 (80%) | G2 (11.1%) | Thomas et al[13], 2012 |
1a- the most common | G3 (7.4%) | ||
G4 (1.2%) | |||
Europe | G1 (60%) | G3 (20%); | Messina et al[43], 2015 |
1b- the most common | G4 (18%) | ||
South-East | G3 (65%) | G1 (25%) | Mao et al[44], 2014 |
Asia | G1 prevails in China, G6 also reported | Li et al[45], 2015 | |
Middle East | G4 (70%) | G1, G2, G6 | Ray et al[46], 2000 |
and North Africa | Ramia et al[47], 2012 | ||
Sub-Saharan and Central Africa | G4 | G5 and G6, G1a, 1b, 2a, 2b | Papastergiou et al[48], 2015 |
South Africa | G 5 | G1, 2, 3, 4 | Gededzha et al[49], 2014 |
Asia Pacific and Latin America | G1a | G 1b, 2a, 2b | Messina et al[43], 2015 |
Ohno et al[50], 1997 | |||
Villar et al[51], 2015 |
- Citation: Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823
- URL: https://www.wjgnet.com/1007-9327/full/v21/i38/10811.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i38.10811